CXCL13 and myeloid sarcoma: First described in SPMS in the early 2000s [36,37], these reports of organized niches with prominent CXCL13 expression sustaining CNS inflammation and autoimmunity have directed attention to the role of the meninges in the pathogenesis of MS.